Sector News

Santen establishes UK subsidiary

November 5, 2014
Life sciences
Japanese drugmaker Santen has set up shop in the UK to help push its recently acquired glaucoma franchise from Merck & Co into the market.
 
The group said it has established a UK subsidiary to promote products such as Saflutan and Cosopt – purchased from Merck back in May for $600 million plus royalties – and help strengthen its footprint in Europe.
 
“The establishment of our own subsidiary in the UK is an important step in achieving our long term corporate vision to become a specialised pharmaceutical company with a global presence”, said Masamichi Sato, Head of Santen European Group and President of Santen Holding EU BV.
 
The move will allow the group to provide its complete portfolio of products throughout Europe, and the launch of commercial teams in other European countries such as Spain, Portugal or Benelux “is expected within the next few months,” he added.
 
By Selina McKee
 
Source: Pharma Times
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend